Literature DB >> 18048875

Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma.

Uwe Wollina1, Michael Buslau, Birgit Heinig, Ivailo Petrov, Eleonore Unger, Eugenia Kyriopoulou, André Koch, Erich Köstler, Jaqueline Schönlebe, Gunther Haroske, Thorsten Doede, Kyrill Pramatarov.   

Abstract

Disabling pansclerotic morphea of childhood (DPMC) is a rare and severe variant of scleroderma. This report presents 3 cases that presented to the authors and studies 25 patients from the literature (English language only) for the presence of chronic nonhealing ulcers of skin and skin cancer. The authors identified a total of 30 patients (9 male and 21 female) aged between 1 and 37 years at time of presentation. All cases were less than 14 years old when the disease started. The majority of patients had an aggressive course with deep sclerotic lesions leading to joint contractures and immobility. Five patients suffered from chronic nonhealing leg ulcers (17%), but ulcers were present on other parts of the body (upper limbs, trunk, head) as well (n = 6). Four patients died because of complications of the disease such as sepsis or gangrene. Two patients developed a squamous cell carcinoma at the age of 16 years and 19 years, respectively (6.7%). The available treatment of DMPC-associated ulcers is unsatisfying. Only temporary improvements have been seen in a minority of patients. We report on marked improvement of chronic leg ulcers by a combination of sildenafil 3 x 20 mg/day and repeated application of a porcine small intestinal submucosal acellular matrix.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18048875     DOI: 10.1177/1534734607308731

Source DB:  PubMed          Journal:  Int J Low Extrem Wounds        ISSN: 1534-7346            Impact factor:   2.057


  9 in total

Review 1.  Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.

Authors:  Han Jie Soh; Courtney Samuel; Victoria Heaton; William Douglas Renton; Angela Cox; Jane Munro
Journal:  Rheumatol Int       Date:  2019-03-05       Impact factor: 2.631

2.  Squamous cell carcinoma and eosinophilia in a long-term course of pansclerotic morphea.

Authors:  Inderjote Grewal; Omar Khan; William Davis
Journal:  BMJ Case Rep       Date:  2014-10-13

3.  [Parallels between wound healing, chronic inflammatory skin diseases and neoplasia: clinical aspects].

Authors:  A Brown; I Tantcheva-Poor; S A Eming
Journal:  Hautarzt       Date:  2014-11       Impact factor: 0.751

4.  [Leg ulcers].

Authors:  U Wollina; L Unger; C Stelzner; J Machetanz; S Schellong
Journal:  Internist (Berl)       Date:  2013-11       Impact factor: 0.743

5.  Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort.

Authors:  Andrew Kim; Nicholas Marinkovich; Rebecca Vasquez; Heidi T Jacobe
Journal:  J Rheumatol       Date:  2013-12-01       Impact factor: 4.666

Review 6.  Overview of Juvenile localized scleroderma and its management.

Authors:  Suzanne C Li; Rong-Jun Zheng
Journal:  World J Pediatr       Date:  2019-11-30       Impact factor: 2.764

Review 7.  Pediatric scleroderma: systemic or localized forms.

Authors:  Kathryn S Torok
Journal:  Pediatr Clin North Am       Date:  2012-04-06       Impact factor: 3.278

Review 8.  Update on Management of Morphea (Localized Scleroderma) in Children.

Authors:  Renu George; Anju George; T Sathish Kumar
Journal:  Indian Dermatol Online J       Date:  2020-03-09

9.  Disabling pansclerotic morphea of childhood--unusual case and management challenges.

Authors:  Ana-Maria Forsea; Aura-Nicoleta Cretu; Ruxandra Ionescu; Calin Giurcaneanu
Journal:  J Med Life       Date:  2008 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.